Treatment preferences for somatostatin analogues in neuroendocrine tumors (NETs) among patients, clinicians and nurses in Australia

#3648

Introduction: Long-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in low-grade pancreatic or midgut neuroendocrine tumors (NETs). Due to the long-term nature of treatment, treatment preferences should be taken into consideration. Funding for this study was provided by Ipsen.

Aim(s): To investigate treatment preferences for LA SSA treatments for NETs among patients, physicians and nurses in Australia.

Materials and methods: A discrete choice experiment (DCE) method was used to analyse treatment preferences for NETs, embedded in an online survey. Participants could choose between 3 hypothetical treatment options: ‘Deep subcutaneous injectable treatment’, ‘deep intramuscular injectable treatment’ or ‘oral treatment’; an opt-out was also provided. Each option was described by seven attributes: Progression free survival (PFS), symptom control for diarrhea and flushing, risk of gastro-intestinal (GI) side effects, frequency of administration, treatment administration, treatment delivery and availability of patient support. A Mixed Multinomial Logit model (MMNL) was used for analysis.

Conference:

Presenting Author:

Authors: Cummins M, Fifer S, Winkler K, Cherian H,

Keywords: Treatment preferences, LA SSAs, NET,